Curis LifesciencesNSE:CURIS 31 Current Ratio is 2.52 as of Mar. 2026, which is 68% above its 10-year median of 1.50. GuruFocus rates NSE:CURIS with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,000 Drug Manufacturers companies, Curis Lifesciences ranks better than 60.3% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Curis Lifesciences's current ratio for the quarter that ended in Mar. 2026 was 2.52.
Curis Lifesciences has a current ratio of 2.52. It generally indicates good short-term financial strength.
The historical rank and industry rank for Curis Lifesciences's Current Ratio or its related term are showing as below:
NSE:CURIS'
s Current Ratio Range Over the Past 10 Years
Min: 0.94 Med: 1.5 Max: 2.52
Current: 2.52
During the past 4 years, Curis Lifesciences's highest Current Ratio was 2.52. The lowest was 0.94. And the median was 1.50.
NSE:CURIS's Current Ratio is ranked better than 60.3% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs NSE:CURIS: 2.52
Curis Lifesciences (NSE:CURIS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Curis Lifesciences Current Ratio Related Terms
Curis Lifesciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences Current Ratio Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Current Ratio
0.94
1.21
1.78
2.52
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
Current Ratio
0.94
1.21
1.78
2.52
NSE:CURIS vs ZTS, UTHR: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences (NSE:CURIS) has a Current Ratio of 2.52 as of Mar. 2026. This is 68% above median its historical median of 1.50. Over the past decade, Curis Lifesciences' Current Ratio has ranged from 0.94 to 2.52. According to the industry distribution chart, Curis Lifesciences ranks #397 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 39.7%.
Is Curis Lifesciences' Current Ratio too high?
Curis Lifesciences' current Current Ratio of 2.52 is 68% above median its 10-year median of 1.50. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 2.52. The Drug Manufacturers industry median Current Ratio is 2.00. Curis Lifesciences' value of 2.52 is 26% above this industry median. Based on the distribution chart, Curis Lifesciences ranks #397 out of 1000 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Curis Lifesciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #397 out of 1000 companies for Current Ratio. This puts Curis Lifesciences in the upper half of its industry. The industry median Current Ratio is 2.00. Curis Lifesciences' value of 2.52 is 26% above this benchmark. Historically, Curis Lifesciences' own Current Ratio has ranged from 0.94 to 2.52 over the past decade. While the company's 10-year median is 1.50 vs. the industry median of 2.00, Curis Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current Current Ratio of 2.52 is 26% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current Current Ratio is 2.52, which is 68% above median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current Current Ratio of 2.52. The current Current Ratio is 2.52, which is 68% above median its 10-year median of 1.50 and 26% above the Drug Manufacturers industry median of 2.00. Curis Lifesciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current Current Ratio is 2.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
31GF Score
Get the complete analysis for NSE:CURIS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 